| Primary |
| Acute Lymphocytic Leukaemia |
62.5% |
| Acute Leukaemia |
12.5% |
| Rigors |
12.5% |
| T-cell Type Acute Leukaemia |
12.5% |
|
| Urticaria |
44.4% |
| Anaphylactic Reaction |
11.1% |
| Pancreatitis |
11.1% |
| Pleural Effusion |
11.1% |
| Unresponsive To Stimuli |
11.1% |
| Vomiting |
11.1% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
44.4% |
| T-cell Type Acute Leukaemia |
20.2% |
| Product Used For Unknown Indication |
10.5% |
| B Precursor Type Acute Leukaemia |
4.7% |
| Lymphocytic Leukaemia |
4.6% |
| Non-hodgkin's Lymphoma |
4.1% |
| Acute Leukaemia |
2.3% |
| Leukaemia Recurrent |
1.9% |
| Acute Lymphocytic Leukaemia Recurrent |
1.6% |
| Prophylaxis |
1.5% |
| Drug Use For Unknown Indication |
0.7% |
| Pain |
0.6% |
| Infection Prophylaxis |
0.6% |
| Antiemetic Supportive Care |
0.5% |
| Gastrostomy Tube Insertion |
0.3% |
| Nausea |
0.3% |
| Sepsis |
0.3% |
| Pyrexia |
0.2% |
| Vomiting |
0.2% |
| Antifungal Prophylaxis |
0.2% |
|
| Sepsis |
15.2% |
| Off Label Use |
11.4% |
| Infection |
7.6% |
| Aspartate Aminotransferase Increased |
5.1% |
| Drug Toxicity |
5.1% |
| Post Transplant Lymphoproliferative Disorder |
5.1% |
| Rhabdomyolysis |
5.1% |
| Toxic Encephalopathy |
5.1% |
| Weight Decreased |
5.1% |
| Anal Ulcer |
3.8% |
| Constipation |
3.8% |
| Death |
3.8% |
| Hypoxia |
3.8% |
| Thrombosis |
3.8% |
| Vomiting |
3.8% |
| Caecitis |
2.5% |
| Cerebral Ischaemia |
2.5% |
| Encephalopathy |
2.5% |
| Epilepsy |
2.5% |
| Hypersensitivity |
2.5% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
19.7% |
| Acute Lymphocytic Leukaemia Recurrent |
8.2% |
| Product Used For Unknown Indication |
8.2% |
| Chemotherapy |
6.6% |
| Prophylaxis |
6.6% |
| B Precursor Type Acute Leukaemia |
4.9% |
| Bone Marrow Conditioning Regimen |
4.9% |
| Nausea |
4.9% |
| Premedication |
4.9% |
| Vomiting |
4.9% |
| Body Temperature Increased |
3.3% |
| Constipation |
3.3% |
| Lymphocytic Leukaemia |
3.3% |
| Pain |
3.3% |
| Prophylaxis Of Nausea And Vomiting |
3.3% |
| T-cell Type Acute Leukaemia |
3.3% |
| Antifungal Prophylaxis |
1.6% |
| Cough |
1.6% |
| Headache |
1.6% |
| Metastases To Meninges |
1.6% |
|
| Acute Lymphocytic Leukaemia |
7.1% |
| Benign Intracranial Hypertension |
7.1% |
| Concomitant Disease Progression |
7.1% |
| Csf Pressure Increased |
7.1% |
| Febrile Bone Marrow Aplasia |
7.1% |
| Hypotension |
7.1% |
| Intracranial Pressure Increased |
7.1% |
| Lactobacillus Infection |
7.1% |
| Peripheral Sensorimotor Neuropathy |
7.1% |
| Prothrombin Level Decreased |
7.1% |
| Sensory Loss |
7.1% |
| Staphylococcal Infection |
7.1% |
| Stenotrophomonas Infection |
7.1% |
| Vomiting |
7.1% |
|
